Stoke Therapeutics, Inc. STOK Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s accounts payable?
- Stoke Therapeutics, Inc. (STOK) reported accounts payable of $6.84M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s accounts payable changed year-over-year?
- Stoke Therapeutics, Inc.'s accounts payable increased by 212.9% year-over-year, from $2.19M to $6.84M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s accounts payable has grown at a 27.0% compound annual growth rate (CAGR), from $1.5M to $4.94M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.